Understanding the Mechanisms of Diastolic Dysfunction

• ClinicalTrials.gov Identifier: NCT03340233
• Recruitment Status: Withdrawn
• First Posted: November 13, 2017
• Last Update Posted: May 1, 2019
• Sponsor: University of California, Los Angeles
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): Daniel Ennis, PhD, University of California, Los Angeles

Study Description

Brief Summary:

Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.

Condition or disease	Intervention/treatment	Phase
Heart Failure With Preserved Ejection Fraction; Healthy	Diagnostic Test: MRI (cardiac) off-label use gadolinium contrast (IND exempt); Diagnostic Test: MRI (cardiac)	Not Applicable

Detailed Description:

The study has three aims. The first aim of the project is to refine MRI techniques using "free-breathing" versus "breath-holding" measurements. Twenty-five normal volunteers will undergo MRI to refine "free-breathing" cardiac imaging and enable construction of patient-specific computer models of the heart. The second aim of the project is to validate and test the myocardial stiffness evaluation framework derived through the first objective in human subjects. Twenty-five normal volunteers will undergo MRI and the data from these images will be compared to specially constructed 3D printed models of the heart, enabling refinement of the EMS framework to separate structural stiffness from material stiffness. The third aim of the project is to measure changes in myocardial stiffness in patients with HFpEF. Thirty-three subjects with current diagnostic criteria for HFpEF will be evaluated at baseline and at six months to evaluate myocardial stiffness and cardiac MRI biomarkers. Specifically, this aim will establish the diagnostic sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: A New Framework for Understanding the Mechanism of Diastolic Dysfunction
• Estimated Study Start Date: June 1, 2018
• Estimated Primary Completion Date: September 2021
• Estimated Study Completion Date: August 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group 1; Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.	Diagnostic Test: MRI (cardiac); MRI without contrast
Experimental: Group 2; Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.	Diagnostic Test: MRI (cardiac); MRI without contrast
Experimental: Group 3; Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.	Diagnostic Test: MRI (cardiac) off-label use gadolinium contrast (IND exempt); Clinical MRI

Outcome Measures

Primary Outcome Measures :

1. The sensitivity of the EMS framework with comparison to cardiac MRI biomarkers of increased stiffness, thereby providing mechanistic insight to one critical underlying cause of HFpEF. [ Time Frame: Five years ]
   Assess the diagnostic sensitivity of MRI method by analyzing baseline and six month longitudinal characteristics in myocardial stiffness measured in patients with HFpEF

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

Healthy volunteers

1. Healthy adults

Patients with Heart Failure with Preserved Ejection Fraction

1. Patient scheduled for catheterization at UCLA Medical Center
2. Ejection fraction >/= 50%
3. Signs and symptoms of heart failure
4. Excluded other potential non-cardiac etiologies of heart failure

Exclusion Criteria:

Healthy volunteers

1. Known medical condition that impacts heart health
2. Contraindications to MRI (e.g., pacemaker/ICD, or claustrophobia)

Patients with Heart Failure with Preserved Ejection Fraction

Exclusion Criteria:

1. Contraindications to MRI (e.g., pacemaker/ICD, or claustrophobia)
2. Prior MI or history of PCI/CABG
3. Worse than mild valvular disease
4. Any indication for ICD implantation
5. Contraindication to MRI contrast agents or eGRF <30 ml/min/1.73m2 or MRI exams (e.g., pacemaker/ICD or claustrophobia).
6. Atrial fibrillation or unstable cardiac rhythm

Contacts and Locations

Locations

United States, California

University of California Los Angeles

Los Angeles, California, United States, 90024

Sponsors and Collaborators

University of California, Los Angeles

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Daniel J Ennis, PhD; University of California, Los Angeles

More Information

• Responsible Party: Daniel Ennis, PhD, Associate Professor, University of California, Los Angeles
• ClinicalTrials.gov Identifier: NCT03340233
• Other Study ID Numbers: IRB#17-000695; 1R01HL131823-01A1 ( U.S. NIH Grant/Contract )
• First Posted: November 13, 2017
• Last Update Posted: May 1, 2019
• Last Verified: April 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Daniel Ennis, PhD, University of California, Los Angeles:

diastolic dysfunction; mechanism; MRI magnetic resonance imaging; ejection fraction

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Cardiovascular Diseases